Key facts
- This page summarizes Reshma Kewalramani's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Jun 2023, 17:07.
Reshma Kewalramani - 16 Jun 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)
- Reporting relationship
- Director
- Issuer ticker
- DNA
- Reported as of
- 16 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2023, 17:07:25 UTC
- Prior SEC filing
- 01 May 2023
- Next SEC filing
- 18 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karen Tepichin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Reshma Kewalramani filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 21 Jun 2023.
Change
- Previous filing in this sequence was filed on 01 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +105,263
- Change %
- Price
- $0.000000
- Shares after
- 105,263
- Date
- 16 Jun 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 105,263
- Exercise price
- $0.000000
- Footnotes
- F1, F2
DNA
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +139,860
- Change %
- Price
- $0.000000
- Shares after
- 139,860
- Date
- 16 Jun 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 139,860
- Exercise price
- $1.90
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Footnote F2
The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023.
Footnote F3
In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.